Menu
GeneBe

MMP9

matrix metallopeptidase 9, the group of M10 matrix metallopeptidases

Basic information

Region (hg38): 20:46008907-46016561

Previous symbols: [ "CLG4B" ]

Links

ENSG00000100985NCBI:4318OMIM:120361HGNC:7176Uniprot:P14780AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • metaphyseal anadysplasia (Supportive), mode of inheritance: AD
  • metaphyseal anadysplasia 2 (Limited), mode of inheritance: Unknown

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Metaphyseal anadysplasia 2ARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingMusculoskeletal4252978; 1867263; 19615667

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the MMP9 gene.

  • not provided (233 variants)
  • Metaphyseal anadysplasia 2 (61 variants)
  • Inborn genetic diseases (18 variants)
  • not specified (4 variants)
  • Mendelian syndromes with cleft lip/palate (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the MMP9 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
47
clinvar
5
clinvar
54
missense
1
clinvar
121
clinvar
5
clinvar
4
clinvar
131
nonsense
1
clinvar
3
clinvar
4
start loss
1
clinvar
1
frameshift
1
clinvar
2
clinvar
1
clinvar
4
inframe indel
1
clinvar
1
clinvar
2
splice donor/acceptor (+/-2bp)
2
clinvar
2
splice region
7
6
3
16
non coding
5
clinvar
20
clinvar
16
clinvar
41
Total 1 2 137 74 25

Highest pathogenic variant AF is 0.0000854

Variants in MMP9

This is a list of pathogenic ClinVar variants found in the MMP9 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
20-46008928-T-A Metaphyseal anadysplasia 2 Uncertain significance (Jan 18, 2024)17107
20-46008941-G-A Likely benign (Oct 23, 2018)793441
20-46008953-G-T Likely benign (Oct 05, 2023)2911737
20-46008954-G-A Uncertain significance (Nov 16, 2022)2728375
20-46008965-G-T Likely benign (Apr 15, 2022)2126556
20-46008971-C-A Likely benign (Aug 16, 2022)2085871
20-46008971-C-T Metaphyseal anadysplasia 2 Benign/Likely benign (Jan 25, 2024)338544
20-46008974-C-T Likely benign (Dec 22, 2023)2167012
20-46008984-G-A Metaphyseal anadysplasia 2 Uncertain significance (Jan 12, 2018)338545
20-46008985-C-T Metaphyseal anadysplasia 2 Benign/Likely benign (Jan 29, 2024)338546
20-46008996-C-T Metaphyseal anadysplasia 2 • MMP9-related disorder Benign/Likely benign (Jan 14, 2024)707836
20-46008997-G-A Uncertain significance (Jun 11, 2023)3002195
20-46009001-G-A Likely benign (Aug 19, 2022)1981818
20-46009006-C-T Metaphyseal anadysplasia 2 Uncertain significance (Nov 28, 2022)1301672
20-46009007-C-T Metaphyseal anadysplasia 2 Conflicting classifications of pathogenicity (Jul 23, 2022)719765
20-46009013-G-T Likely benign (May 27, 2022)1595888
20-46009019-C-T Likely benign (Aug 01, 2022)2020584
20-46009020-C-T not specified Uncertain significance (Mar 07, 2024)3170134
20-46009035-A-G Uncertain significance (Apr 20, 2020)1042984
20-46009039-A-G Metaphyseal anadysplasia 2 Benign (Feb 01, 2024)708035
20-46009046-C-T Likely benign (Mar 15, 2021)1657817
20-46009047-G-A not specified Uncertain significance (Jan 17, 2024)1057022
20-46009713-A-G Likely benign (Mar 06, 2019)1198083
20-46009861-C-T Metaphyseal anadysplasia 2 Conflicting classifications of pathogenicity (May 28, 2023)898779
20-46009863-C-T Uncertain significance (Nov 04, 2022)2029927

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
MMP9protein_codingprotein_codingENST00000372330 137654
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.89e-170.025612551422321257480.000931
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.4154164410.9440.00002904518
Missense in Polyphen144147.630.975391572
Synonymous0.1471961990.9870.00001521452
Loss of Function0.6312831.80.8790.00000148344

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0006810.000680
Ashkenazi Jewish0.01010.0101
East Asian0.0007620.000761
Finnish0.000.00
European (Non-Finnish)0.0007400.000721
Middle Eastern0.0007620.000761
South Asian0.0004580.000457
Other0.0006520.000652

dbNSFP

Source: dbNSFP

Function
FUNCTION: May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide. {ECO:0000269|PubMed:1480034}.;
Disease
DISEASE: Intervertebral disc disease (IDD) [MIM:603932]: A common musculo-skeletal disorder caused by degeneration of intervertebral disks of the lumbar spine. It results in low-back pain and unilateral leg pain. {ECO:0000269|PubMed:18455130}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Metaphyseal anadysplasia 2 (MANDP2) [MIM:613073]: A bone development disorder characterized by skeletal anomalies that resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia. {ECO:0000269|PubMed:19615667}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Relaxin signaling pathway - Homo sapiens (human);Bladder cancer - Homo sapiens (human);TNF signaling pathway - Homo sapiens (human);Prostate cancer - Homo sapiens (human);Estrogen signaling pathway - Homo sapiens (human);Fluid shear stress and atherosclerosis - Homo sapiens (human);IL-17 signaling pathway - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);MicroRNAs in cancer - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Transcriptional misregulation in cancer - Homo sapiens (human);Hepatitis B - Homo sapiens (human);Leukocyte transendothelial migration - Homo sapiens (human);Celecoxib Pathway, Pharmacodynamics;Matrix Metalloproteinases;Osteopontin Signaling;Angiogenesis;Angiogenesis overview;TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway;AGE-RAGE pathway;Spinal Cord Injury;Mammary gland development pathway - Involution (Stage 4 of 4);IL1 and megakaryocytes in obesity;Photodynamic therapy-induced NF-kB survival signaling;Lung fibrosis;Interleukin-4 and 13 signaling;EMT transition in Colorectal Cancer;Endochondral Ossification;Neutrophil degranulation;Assembly of collagen fibrils and other multimeric structures;Signal Transduction;inhibition of matrix metalloproteinases;Collagen degradation;Collagen formation;Extracellular matrix organization;Innate Immune System;Immune System;Activation of Matrix Metalloproteinases;CXCR4-mediated signaling events;Degradation of the extracellular matrix;Signaling by SCF-KIT;Signaling by Receptor Tyrosine Kinases;Osteopontin-mediated events;Regulation of nuclear beta catenin signaling and target gene transcription;LPA receptor mediated events;Validated targets of C-MYC transcriptional activation;AP-1 transcription factor network;Syndecan-1-mediated signaling events;amb2 Integrin signaling;Plasma membrane estrogen receptor signaling;Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling;Validated transcriptional targets of AP1 family members Fra1 and Fra2;Syndecan-4-mediated signaling events;FGF signaling pathway (Consensus)

Recessive Scores

pRec
0.972

Intolerance Scores

loftool
0.926
rvis_EVS
0.67
rvis_percentile_EVS
84.68

Haploinsufficiency Scores

pHI
0.240
hipred
N
hipred_score
0.382
ghis
0.453

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.556

Gene Damage Prediction

AllRecessiveDominant
MendelianHighHighHigh
Primary ImmunodeficiencyHighHighHigh
CancerHighHighHigh

Mouse Genome Informatics

Gene name
Mmp9
Phenotype
homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; immune system phenotype; vision/eye phenotype; digestive/alimentary phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); neoplasm; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype;

Zebrafish Information Network

Gene name
mmp9
Affected structure
mandibular arch skeleton
Phenotype tag
abnormal
Phenotype quality
morphology

Gene ontology

Biological process
skeletal system development;ossification;positive regulation of protein phosphorylation;proteolysis;embryo implantation;cytokine-mediated signaling pathway;extracellular matrix disassembly;extracellular matrix organization;macrophage differentiation;positive regulation of cell migration;collagen catabolic process;cellular response to reactive oxygen species;endodermal cell differentiation;negative regulation of apoptotic process;neutrophil degranulation;positive regulation of DNA binding;positive regulation of epidermal growth factor receptor signaling pathway;ephrin receptor signaling pathway;leukocyte migration;positive regulation of keratinocyte migration;cellular response to cadmium ion;positive regulation of release of cytochrome c from mitochondria;regulation of neuroinflammatory response;positive regulation of receptor binding;positive regulation of vascular smooth muscle cell proliferation;negative regulation of intrinsic apoptotic signaling pathway;negative regulation of cation channel activity;negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
Cellular component
extracellular region;extracellular space;collagen-containing extracellular matrix;extracellular exosome;tertiary granule lumen;ficolin-1-rich granule lumen
Molecular function
endopeptidase activity;metalloendopeptidase activity;serine-type endopeptidase activity;protein binding;collagen binding;metallopeptidase activity;zinc ion binding;identical protein binding